Aptevo Says Mipletamig Combination Enabled 21% of Frontline AML Patients to Reach Transplant
The report describes a clinical outcome for Aptevo’s mipletamig combination in frontline AML patients.
The report describes a clinical outcome for Aptevo’s mipletamig combination in frontline AML patients.